Maxigesic approval positive for AFT Pharmaceuticals

Maxigesic approval positive for AFT Pharmaceuticals
AFT founder and managing director Hartley Atkinson. (Image: Supplied)
Tamara Poi-Ngawhika
 AFT Pharmaceuticals, the owner of Maxigesic, offers investors a “large opportunity but with a high degree of uncertainty”, according to Forsyth Barr analysts.The New Zealand stock exchange-listed company has just announced its rapid-release tablet form of Maxigesic has been granted approval by the United States Food and Drug Administration (FDA) for use in the country.Breaking into the US market is difficult because getting FDA approval can be challenging. AFT said the US market is worth about US$7.16 billion (NZ$11.5b) and is...

More Markets

Oceania forecasts sales lift as it targets debt
Property

Oceania forecasts sales lift as it targets debt

It said sales applications had lifted 23% between July and August.

New structure, powers for ComCom
Markets

New structure, powers for ComCom

Groceries, aviation, building supplies, digital services carparking all get a mention.

NZME shareholder Jim Grenon lifts investment in media firm
Markets

NZME shareholder Jim Grenon lifts investment in media firm

NZME shareholder and director Jim Grenon has lifted his investment in the media business for the second time in recent weeks, to just under 18%.A notice to the NZX on Monday stated Grenon had lifted his shareholding from 15.963% to 17.932%, after acquiring 3.7 million shares for...

‘Unusual’ volume of CCCFA changes in focus
Finance

‘Unusual’ volume of CCCFA changes in focus

Select committee mulls proposed changes to CCCFA, to report recommendations Oct 20.